SCHEMBL1177463

SCHEMBL1177463

O=C(c1ccc(CN2CCCCC2)cc1)N1CCN(C2CCCCC2)CC1

nearest known ligand 0.77

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.77
L3MBTL3 Q96JM7 6/20 0.76
L3MBTL1 Q9Y468 5/20 0.76
MBTD1 Q05BQ5 5/20 0.76
KDM4E B2RXH2 3/20 0.61
POLB P06746 1/20 0.61
ALDH1A1 P00352 1/20 0.61
HPGD P15428 1/20 0.60
TP53BP1 Q12888 1/20 0.58
L3MBTL4 Q8NA19 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1449909 0.87 HRH3 (1.00) HRH3L3MBTL3L3MBTL1MBTD1KDM4E
SCHEMBL23718118 0.86 L3MBTL3 (1.00) HRH3L3MBTL3L3MBTL1MBTD1KDM4E
SCHEMBL1449894 0.86 HRH3 (0.76) HRH3L3MBTL3L3MBTL1MBTD1KDM4E
SCHEMBL522796 0.86 HRH3 (1.00) HRH3L3MBTL3L3MBTL1MBTD1HPGD
Hydrochloric Acid SCHEMBL1450634 0.85 HRH3 (0.98) HRH3L3MBTL3L3MBTL1MBTD1HPGD
SCHEMBL1449310 0.84 HRH3 (1.00) HRH3L3MBTL3L3MBTL1MBTD1KDM4E
Bavisant SCHEMBL522603 0.83 HRH3 (1.00) HRH3L3MBTL3L3MBTL1MBTD1HPGD
SCHEMBL1449644 0.83 HRH3 (0.75) HRH3L3MBTL3L3MBTL1MBTD1KDM4E
SCHEMBL10264586 0.82 L3MBTL3 (0.69) HRH3L3MBTL3L3MBTL1MBTD1KDM4E
Bavisant SCHEMBL521755 0.82 HRH3 (1.00) HRH3L3MBTL3L3MBTL1MBTD1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558595-B1 PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES JANSSEN PHARMACEUTICA NV (BE) 2009-11-25 EP claimed
US-20080056991-A1 PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES APODACA RICHARD L 2008-03-06 US claimed
CN-1729180-A Piperazinyl and diazapanyl benzamides and benzthioamides JANSSEN PHARMACEUTICA NV (BE) 2006-02-01 CN claimed
EP-1558595-A1 PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 2005-08-03 EP claimed
US-20040110746-A1 Piperazinyl and diazapanyl benzamides and benzthioamides JANSSEN PHARMACEUTICA N.V. (BE) 2004-06-10 US claimed
WO-2004037801-A1 PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES JANSSEN PHARMACEUTICA, N.V. (BE) 2004-05-06 WO claimed
US-8680273-B2 Process for the preparation of piperazinyl and diazepanyl benzamide derivatives JANSSEN PHARMACEUTICA NV (BE) 2014-03-25 US disclosed
EP-2404911-A1 Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives Janssen Pharmaceutica NV (BE) 2012-01-11 EP disclosed
US-20110105752-A1 PROCESS FOR THE PREPARATION OF PIPERAZINYL AND DIAZEPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2011-05-05 US disclosed
US-7893257-B2 Reacting 4-Morpholin-4-ylmethyl-benzoic acid with 1-cyclopropyl-piperazine dihydrochloride producing (4-Cyclopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone; sleep disorders, attention deficit hyperactivity disorders (ADHD), learning and memory disorders JANSSEN PHARMACEUTICA NV (BE) 2011-02-22 US disclosed
US-20100197689-A1 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2010-08-05 US disclosed
US-7728129-B2 Processes for the preparation of piperazinyl and diazapanyl benzamide derivatives JANSSEN PHARMACEUTICA NV (BE) 2010-06-01 US disclosed
EP-2121636-A2 PROCESS FOR THE PREPARATION OF PIPERAZINYL AND DIAZEPANYL BENZAMIDE DERIVATIVES Janssen Pharmaceutica, N.V. (BE) 2009-11-25 EP disclosed
US-20080056991-A1 PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES APODACA RICHARD L 2008-03-06 US disclosed
US-20070197508-A1 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-23 US disclosed
WO-2007053427-A2 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-10 WO disclosed
CN-1729180-A Piperazinyl and diazapanyl benzamides and benzthioamides JANSSEN PHARMACEUTICA NV (BE) 2006-02-01 CN disclosed
EP-1558595-A1 PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 2005-08-03 EP disclosed
US-20040110746-A1 Piperazinyl and diazapanyl benzamides and benzthioamides JANSSEN PHARMACEUTICA N.V. (BE) 2004-06-10 US disclosed
WO-2004037801-A1 PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES JANSSEN PHARMACEUTICA, N.V. (BE) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197508-A1 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES HRH2, HRH4, HRH1 HRH3 4/4885L3MBTL3 4857/4885L3MBTL1 4823/4885
US-20080056991-A1 PIPERAZINYL AND DIAZAPANYL BENZAMIDES AND BENZTHIOAMIDES HRH2, HNMT, HRH3 HRH3 3/4885L3MBTL3 4801/4885L3MBTL1 4656/4885
US-20100197689-A1 NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES HRH2, HRH4, HRH1 HRH3 4/4885L3MBTL3 4857/4885L3MBTL1 4823/4885
US-20040110746-A1 Piperazinyl and diazapanyl benzamides and benzthioamides HRH2, HNMT, HRH3 HRH3 3/4885L3MBTL3 4801/4885L3MBTL1 4656/4885
US-20110105752-A1 PROCESS FOR THE PREPARATION OF PIPERAZINYL AND DIAZEPANYL BENZAMIDE DERIVATIVES HRH4, HRH3, HRH2 HRH3 2/4885L3MBTL3 4717/4885L3MBTL1 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.